Mon, May 23, 2022

David Risinger Initiated (VRTX) at Hold and Held Target at $265 on, May 23rd, 2022

David Risinger of SVB Leerink, Initiated "Vertex Pharmaceuticals Incorporated" (VRTX) at Hold and Held Target at $265 on, May 23rd, 2022.

David has made no other calls on VRTX in the last 4 months.



There are 11 other peers that have a rating on VRTX. Out of the 11 peers that are also analyzing VRTX, 5 agree with David's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Brian Abrahams of "RBC Capital" Maintained at Hold with Decreased Target to $267 on, Friday, May 6th, 2022
  • Brian Skorney of "Baird" Downgraded from Buy to Hold on, Friday, May 6th, 2022
  • Do Kim of "Piper Sandler" Maintained at Hold with Decreased Target to $242 on, Friday, May 6th, 2022
  • Paul Matteis of "Stifel" Maintained at Hold with Increased Target to $240 on, Thursday, May 5th, 2022
  • Matthew Harrison of "Morgan Stanley" Upgraded from Sell to Hold and Held Target at $250 on, Tuesday, May 3rd, 2022


These are the ratings of the 6 analyists that currently disagree with David


  • Liisa Bayko of "Evercore ISI Group" Maintained at Buy and Held Target at $278 on, Monday, May 9th, 2022
  • Mohit Bansal of "Wells Fargo" Maintained at Buy with Increased Target to $305 on, Friday, May 6th, 2022
  • Gena Wang of "Barclays" Maintained at Buy and Held Target at $291 on, Thursday, May 5th, 2022
  • Colin Bristow of "UBS" Maintained at Strong Buy with Decreased Target to $322 on, Wednesday, April 27th, 2022
  • Hartaj Singh of "Oppenheimer" Maintained at Buy with Increased Target to $350 on, Monday, April 4th, 2022
  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy and Held Target at $275 on, Thursday, January 27th, 2022